Loading clinical trials...
Loading clinical trials...
A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Conditions
Interventions
(vic-)trastuzumab duocarmazine
Physician's choice
Locations
90
United States
Southern Cancer Center
Mobile, Alabama, United States
Arizona Clinical Research Center
Tucson, Arizona, United States
Moores UCSD Cancer Center
San Diego, California, United States
Woodlands Medical Specialists
Pensacola, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Start Date
December 15, 2017
Primary Completion Date
March 31, 2021
Completion Date
June 30, 2022
Last Updated
October 19, 2023
NCT05468034
NCT07347600
NCT07085767
NCT05660083
NCT07354022
NCT02422641
Lead Sponsor
Byondis B.V.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions